Leonardo Mariño-Repizo

Dr. Leonardo Mariño-Repizo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2025 in Free Radical Research
Verified
Journal Article
Closed access
PHPaul Emir Hasuoka
Paul Emir Hasuoka
FTFranco Tonelli
Franco Tonelli
LMLeonardo Mariño-Repizo
Leonardo Mariño-Repizo
PPPablo Pacheco
Pablo Pacheco
Selenomethionine (SeMet) increases glutathione peroxidase (GPx) activity, a seleno-enzyme with an antioxidant function that counteracts reactive oxygen species (ROS). After ablation, transplant organs generate ROS during irrigation-reperfusion injury. GPx1 can be downregulated during hypoxia in ablated organs. ROS can oxidize proteins, inducing proteolysis, which compromises the transplant outcome. SeMet administration to living donors can decrease proteolysis in transplant organs, improving their preservation. Accordingly, SeMet was administered to rats for 7 days. After this period, the liver, heart, and kidneys were ablated, and proteins extracted at different postmortem intervals (PMI). Total protein analysis showed a lower protein concentration decrease in kidneys and heart from SeMet-supplemented rats after a 6 hs PMI. Molecular weight changes of proteins to proteolysis products (PPs) were studied by size exclusion chromatography (SEC). SeMet decreased PPs (<29.5 kDa) in the liver, kidneys, and heart. Specific analysis of GPx1 proteolysis by affinity chromatography coupled to inductively coupled plasma mass spectrometry (AF-ICP-MS) showed that SeMet administration decreased GPx1 proteolysis 24% in the liver and 16.8% in the heart. SeMet administration reduced the proteolysis velocity of GPx1 (VGPx1) in heart. SeMet administration to living donors for seven days decreased proteolysis in transplant organs, improving its conservation.

Verified
Journal Article
Open access
PDF file
MDMaría Belén Delsouc
María Belén Delsouc
RCRocío Ayelem Conforti
Rocío Ayelem Conforti
AZAna Sofia Zabala
Ana Sofia Zabala
VFVeronica Filippa
Veronica Filippa
LMLeonardo Mariño-Repizo
Leonardo Mariño-Repizo
MCMarilina Casais
Marilina Casais
Endometriosis (EDT) is a chronic, estrogen-dependent disease characterized by inflammation, fibrosis, pelvic pain, and infertility. Current therapies show limited long-term efficacy and adverse effects, underscoring the need for novel therapeutic approaches. Elevated copper (Cu) levels have been reported in both patients and animal models of EDT, making Cu chelation a promising strategy. This work aimed to evaluate the impact of ammonium tetrathiomolybdate (TM) on the expression of markers related to the interconnected processes of inflammation, innervation, and fibrogenesis in mice with induced EDT. Twenty-four female C57BL/6 mice were assigned to Sham, EDT, or EDT+TM groups. Treatment with TM began on postoperative day 15, with samples collected one month after EDT induction. Peritoneal fluid cytokines (TNF-α, IL-1β, IL-6, TGF-β1) were quantified by ELISA. Endometriotic-like lesions were examined for mRNA expression of cytokines, neurotrophins (Ngf, Bdnf, Ngfr), neural markers (Uchl1, Gap43), neuropeptides and nociceptive markers (Tac1/Tacr1, Calca/Calcrl/Ramp1, Trpv1), and fibrogenic markers (Vim, Acta2, Col1a1, Fmod) by RT-qPCR. Neurotrophin protein levels were measured by ELISA, and collagen content was assessed through Masson’s staining. TM significantly modulated inflammatory, neural, nociceptive, and fibrogenic markers, reducing most of them along with collagen content. These findings suggest that TM could impact key pathological mechanisms involved in EDT.